Clinical Trial Update: Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of furmonertinib and anlotinib in patients with EGFR-mutant lung adenocarcinoma with brain metastases; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma with Brain Metastases

Drugs mentioned

• Anlotinib (anlotinib)
• Furmonertinib (furmonertinib)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Adenocarcinoma of Lung Metastatic to Brain | Phase 2 | Status: NOT_YET_RECRUITING